BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 22705984)

  • 21. Clinicopathological and molecular genomic features of monomorphic epitheliotropic intestinal T-cell lymphoma in the Chinese population: a study of 20 cases.
    Chen C; Gong Y; Yang Y; Xia Q; Rao Q; Shao Y; Zhu L; Zhang J; Li X; Ji P; Zhai B; Zhang X; Zhang Z
    Diagn Pathol; 2021 Dec; 16(1):114. PubMed ID: 34895266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.
    Thoma G; Nuninger F; Falchetto R; Hermes E; Tavares GA; Vangrevelinghe E; Zerwes HG
    J Med Chem; 2011 Jan; 54(1):284-8. PubMed ID: 21155605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
    Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
    Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.
    Ehrentraut S; Schneider B; Nagel S; Pommerenke C; Quentmeier H; Geffers R; Feist M; Kaufmann M; Meyer C; Kadin ME; Drexler HG; MacLeod RA
    Oncotarget; 2016 Jun; 7(23):34201-16. PubMed ID: 27144517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
    Degryse S; Bornschein S; de Bock CE; Leroy E; Vanden Bempt M; Demeyer S; Jacobs K; Geerdens E; Gielen O; Soulier J; Harrison CJ; Constantinescu SN; Cools J
    Blood; 2018 Jan; 131(4):421-425. PubMed ID: 29187379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring of the immunomodulatory effect of CP-690,550 by analysis of the JAK/STAT pathway in kidney transplant patients.
    Quaedackers ME; Mol W; Korevaar SS; van Gurp EA; van Ijcken WF; Chan G; Weimar W; Baan CC
    Transplantation; 2009 Oct; 88(8):1002-9. PubMed ID: 19855246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK3-STAT pathway blocking benefits in experimental lupus nephritis.
    Ripoll È; de Ramon L; Draibe Bordignon J; Merino A; Bolaños N; Goma M; Cruzado JM; Grinyó JM; Torras J
    Arthritis Res Ther; 2016 Jun; 18(1):134. PubMed ID: 27278657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients.
    van Gurp EA; Schoordijk-Verschoor W; Klepper M; Korevaar SS; Chan G; Weimar W; Baan CC
    Transplantation; 2009 Jan; 87(1):79-86. PubMed ID: 19136895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.
    López C; Bergmann AK; Paul U; Murga Penas EM; Nagel I; Betts MJ; Johansson P; Ritgen M; Baumann T; Aymerich M; Jayne S; Russell RB; Campo E; Dyer MJ; Dürig J; Siebert R
    Br J Haematol; 2016 Apr; 173(2):265-73. PubMed ID: 26917488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
    Elliott NE; Cleveland SM; Grann V; Janik J; Waldmann TA; Davé UP
    Blood; 2011 Oct; 118(14):3911-21. PubMed ID: 21821710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes.
    Gehringer M; Pfaffenrot E; Bauer S; Laufer SA
    ChemMedChem; 2014 Feb; 9(2):277-81. PubMed ID: 24403205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia.
    Kiel MJ; Velusamy T; Rolland D; Sahasrabuddhe AA; Chung F; Bailey NG; Schrader A; Li B; Li JZ; Ozel AB; Betz BL; Miranda RN; Medeiros LJ; Zhao L; Herling M; Lim MS; Elenitoba-Johnson KS
    Blood; 2014 Aug; 124(9):1460-72. PubMed ID: 24825865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.
    Waldmann TA
    Mol Cell Endocrinol; 2017 Aug; 451():66-70. PubMed ID: 28214593
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia.
    Yin C; Sandoval C; Baeg GH
    Leuk Lymphoma; 2015 May; 56(5):1502-6. PubMed ID: 25146434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. WP1066 exhibits antitumor efficacy in nasal‑type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway.
    Geng L; Li X; Zhou X; Fang X; Yuan D; Wang X
    Oncol Rep; 2016 Nov; 36(5):2868-2874. PubMed ID: 27633398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
    Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
    Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
    Kameda T; Shide K; Shimoda HK; Hidaka T; Kubuki Y; Katayose K; Taniguchi Y; Sekine M; Kamiunntenn A; Maeda K; Nagata K; Matsunaga T; Shimoda K
    Int J Hematol; 2010 Sep; 92(2):320-5. PubMed ID: 20697856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome.
    Sato T; Toki T; Kanezaki R; Xu G; Terui K; Kanegane H; Miura M; Adachi S; Migita M; Morinaga S; Nakano T; Endo M; Kojima S; Kiyoi H; Mano H; Ito E
    Br J Haematol; 2008 May; 141(5):681-8. PubMed ID: 18397343
    [TBL] [Abstract][Full Text] [Related]  

  • 40. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma.
    Nairismägi ML; Tan J; Lim JQ; Nagarajan S; Ng CC; Rajasegaran V; Huang D; Lim WK; Laurensia Y; Wijaya GC; Li ZM; Cutcutache I; Pang WL; Thangaraju S; Ha J; Khoo LP; Chin ST; Dey S; Poore G; Tan LH; Koh HK; Sabai K; Rao HL; Chuah KL; Ho YH; Ng SB; Chuang SS; Zhang F; Liu YH; Pongpruttipan T; Ko YH; Cheah PL; Karim N; Chng WJ; Tang T; Tao M; Tay K; Farid M; Quek R; Rozen SG; Tan P; Teh BT; Lim ST; Tan SY; Ong CK
    Leukemia; 2016 Jun; 30(6):1311-9. PubMed ID: 26854024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.